---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104020"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:05:11.481453+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio reports Q2 net loss $10.2M; ABI-6250 shows 4-day half-life supporting once-daily dosing

## Summary
- Net loss $10.2M ($1.33/share) vs $11.2M ($1.98/share) in Q2 2024; revenue from Gilead collaboration $9.6M.
- Cash $75.0M as of June 30, 2025, projected to fund operations into mid-2026.
- ABI-6250 Phase 1a interim: mean half-life ~4 days supports once-daily oral dosing; dose-dependent bile acid elevations show NTCP target engagement.
- Safety: all AEs grade 1-2; one grade 2 ALT elevation at highest single dose (25 mg), self-limited, no serious AEs.
- Phase 1b herpes data (ABI-5366, ABI-1179) on track for fall 2025; positive Phase 1b data for ABI-4334 (HBV) reported earlier.

## SEC filing metadata
- accession: 0000950170-25-104020
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017025104020/0000950170-25-104020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017025104020/asmb-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104020
- JSON: https://secwatch.observer/filing/0000950170-25-104020.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.